Your browser doesn't support javascript.
loading
[Human growth hormone and Turner syndrome]. / Hormona de crecimiento y síndrome de Turner.
Sánchez Marco, Silvia Beatriz; de Arriba Muñoz, Antonio; Ferrer Lozano, Marta; Labarta Aizpún, José Ignacio; Garagorri Otero, Jesús María.
Afiliação
  • Sánchez Marco SB; Unidad de Endocrinología Pediátrica, Hospital Universitario Miguel Servet, Zaragoza, España. Electronic address: ssanchezmarco@gmail.com.
  • de Arriba Muñoz A; Unidad de Endocrinología Pediátrica, Hospital Universitario Miguel Servet, Zaragoza, España.
  • Ferrer Lozano M; Unidad de Endocrinología Pediátrica, Hospital Universitario Miguel Servet, Zaragoza, España.
  • Labarta Aizpún JI; Unidad de Endocrinología Pediátrica, Hospital Universitario Miguel Servet, Zaragoza, España.
  • Garagorri Otero JM; Servicio de Pediatría, Hospital Clínico Universitario Lozano Blesa, Zaragoza, España.
An Pediatr (Barc) ; 86(2): 81-86, 2017 Feb.
Article em Es | MEDLINE | ID: mdl-27179405
ABSTRACT

OBJECTIVE:

The evaluation of clinical and analytical parameters as predictors of the final growth response in Turner syndrome patients treated with growth hormone. MATERIAL AND

METHODS:

A retrospective study was performed on 25 girls with Turner syndrome (17 treated with growth hormone), followed-up until adult height. Auxological, analytical, genetic and pharmacological parameters were collected. A descriptive and analytical study was conducted to evaluate short (12 months) and long term response to treatment with growth hormone.

RESULTS:

A favourable treatment response was shown during the first year of treatment in terms of height velocity gain in 66.6% of cases (height-gain velocity >3cm/year). A favourable long-term treatment response was also observed in terms of adult height, which increased by 42.82±21.23cm (1.25±0.76 SDS), with an adult height gain of 9.59±5.39cm (1.68±1.51 SDS).

CONCLUSIONS:

Predictors of good response to growth hormone treatment are A) initial growth hormone dose, B) time on growth hormone treatment until starting oestrogen therapy, C) increased IGF1 and IGFBP-3 levels in the first year of treatment, and D) height gain velocity in the first year of treatment.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndrome de Turner / Hormônio do Crescimento Humano Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Adolescent / Child / Child, preschool / Female / Humans / Infant Idioma: Es Revista: An Pediatr (Barc) Assunto da revista: PEDIATRIA Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndrome de Turner / Hormônio do Crescimento Humano Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Adolescent / Child / Child, preschool / Female / Humans / Infant Idioma: Es Revista: An Pediatr (Barc) Assunto da revista: PEDIATRIA Ano de publicação: 2017 Tipo de documento: Article